JAK1 Inhibitor Ivarmacitinib Reversing Immunotherapy Resistance in TNBC

NCT06731153 · clinicaltrials.gov ↗

PHASE2

Phase

NOT_YET_RECRUITING

Status

40

Enrollment

OTHER

Sponsor class

Conditions

Triple Negative Breast Cancer (TNBC)
Metastatic Breast Cancer

Interventions

DRUG: Ivarmacitinib
DRUG: Camrelizumab (SHR-1210)
DRUG: Eribulin

Sponsor

Fudan University